Ono Pharmaceutical CoMEX:4528N 88 PEG Ratio is 17.16 as of Jun. 29, 2026, which is 1669% above its 10-year median of 0.97. GuruFocus rates MEX:4528N with a GF Score™ of 88/100 and a GF Value™ of MXN324.16. The stock has 2 warning signs investors should review. Among 346 Drug Manufacturers companies, Ono Pharmaceutical Co ranks worse than 91.62% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Ono Pharmaceutical Co's PEG Ratio or its related term are showing as below:
MEX:4528N'
s PEG Ratio Range Over the Past 10 Years
Min: 0.38 Med: 0.97 Max: 23.66
Current: 14.56
During the past 13 years, Ono Pharmaceutical Co's highest PEG Ratio was 23.66. The lowest was 0.38. And the median was 0.97.
MEX:4528N's PEG Ratio is ranked worse than 91.62% of 346
companies
in the Drug Manufacturers industry
Industry Median: 1.715
vs MEX:4528N: 14.56
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Ono Pharmaceutical Co (MEX:4528N) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Ono Pharmaceutical Co's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ono Pharmaceutical Co PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ono Pharmaceutical Co's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Ono Pharmaceutical Co's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Ono Pharmaceutical Co (MEX:4528N) has a PEG Ratio of 17.16 as of Jun. 29, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Ono Pharmaceutical Co and its competitors. This is 1669% above median its historical median of 0.97. Over the past decade, Ono Pharmaceutical Co's PEG Ratio has ranged from 0.38 to 23.66. According to the industry distribution chart, Ono Pharmaceutical Co ranks #317 out of 346 companies in the Drug Manufacturers industry, placing it in the top 91.6%.
Is Ono Pharmaceutical Co's PEG Ratio too high?
Ono Pharmaceutical Co's current PEG Ratio of 17.16 is 1669% above median its 10-year median of 0.97. Over the past 10 years, this metric has ranged from a low of 0.38 to a high of 23.66. The Drug Manufacturers industry median PEG Ratio is 1.72. Ono Pharmaceutical Co's value of 17.16 is 900.6% above this industry median. Based on the distribution chart, Ono Pharmaceutical Co ranks #317 out of 346 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Ono Pharmaceutical Co has a GF Score™ of 88/100, reflecting its overall financial health beyond just this single metric.
How does Ono Pharmaceutical Co's PEG Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Ono Pharmaceutical Co ranks #317 out of 346 companies for PEG Ratio. This places Ono Pharmaceutical Co in the lower half of its industry. The industry median PEG Ratio is 1.72. Ono Pharmaceutical Co's value of 17.16 is 900.6% above this benchmark. Historically, Ono Pharmaceutical Co's own PEG Ratio has ranged from 0.38 to 23.66 over the past decade. While the company's 10-year median is 0.97 vs. the industry median of 1.72, Ono Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.72, based on 346 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ono Pharmaceutical Co's current PEG Ratio of 17.16 is 900.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Ono Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ono Pharmaceutical Co's current PEG Ratio is 17.16, which is 1669% above median its own 10-year median of 0.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ono Pharmaceutical Co stock overvalued right now?
Ono Pharmaceutical Co (MEX:4528N) has a current PEG Ratio of 17.16. The stock's GF Value™ is MXN324.16, compared to a current price of MXN341.69 — trading 5.4% above its estimated fair value. The current PEG Ratio is 17.16, which is 1669% above median its 10-year median of 0.97 and 900.6% above the Drug Manufacturers industry median of 1.72. Ono Pharmaceutical Co's overall GF Score™ is 88/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Ono Pharmaceutical Co (MEX:4528N), the current PEG Ratio is 17.16 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ono Pharmaceutical Co (MEX:4528N) Overvalued in 2026?
Based on GuruFocus' analysis, Ono Pharmaceutical Co stock appears to be overvalued.
The current stock price of MXN341.69 is trading 5.4% above its estimated GF Value™ of MXN324.16.
Key valuation signals for MEX:4528N:
PEG Ratio: 17.16 (1669% above median its 10-year median of 0.97)
GF Value™: MXN324.16 vs. price of MXN341.69 (5.4% above fair value)
Industry Position: 900.6% above the Drug Manufacturers median (#317 of 346)
No single metric tells the full story. See the MEX:4528N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ono Pharmaceutical Co Ltd is a drug manufacturer with a focus on drug discovery in areas of unmet medical needs. The vast majority of the company's revenue is derived from its circulatory and respiratory drugs, followed by its metabolic drugs and vitamins. The company also reports revenue derived from royalties. The bulk of the company's sales is generated in Japan, followed by the rest of Asia and Europe.
88GF Score
Get the complete analysis for MEX:4528N
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:4528N has been successfully added to your 
